Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2024 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
May 23, 2024 17:10 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor...
May 09, 2024 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation...
April 24, 2024 16:05 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
April 09, 2024 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for...
April 04, 2024 16:05 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
March 22, 2024 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
March 06, 2024 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
February 28, 2024 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - -...
February 07, 2024 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics to Present at Upcoming Conferences

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...